Overview

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Status:
Terminated
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis. This study consists of three cohorts with 16-week treatment period per cohort that will be conducted sequentially.
Phase:
Phase 2
Details
Lead Sponsor:
Bridge Biotherapeutics, Inc.
Collaborator:
KCRN Research, LLC